AlidaBio, founded in 2020, is revolutionizing the field of epigenomics by commercializing accessible tools that broaden the application of epitranscriptomics in life sciences. The firm's groundbreaking products empower researchers to concurrently analyze multiple RNA modifications with relative quantification, using RNA inputs suitable for clinically relevant samples and supported by user-friendly bioinformatics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/13/24 | $7,500,000 | Series A |
FusionX Ventures Genoa Ventures  Vertical Venture Partners | undisclosed |
